论文部分内容阅读
目的 :探讨多肿瘤抑制基因编码的 P16蛋白表达与卵巢癌生物学特性及患者预后的相关性。方法 :应用免疫组织化学S- P法检测 5 8例人卵巢癌组织中 P16蛋白的表达。 结果 :(1) P16蛋白在不同病理组织学类型的卵巢癌组织中阳性表达率不同 ,表现为低分化腺癌的阳性表达率低于交界性肿瘤 ,两者相差显著 (P<0 .0 5 )。 (2 )术中发现有淋巴结及网膜转移的患者 ,其卵巢癌组织中 P16蛋白的阳性表达率低于无转移者 ,两者相差非常显著 (P<0 .0 1) ;但其阳性率在原发灶与转移灶间相差不显著 (P>0 .0 5 )。 (3)术后存活期小于或等于 2年的患者 ,其卵巢癌组织中 P16蛋白的阳性表达率低于术后存活时间大于 2年者 ,两者相差显著 (P<0 .0 5 )。结论 :P16蛋白在抑制卵巢癌的发生发展中起重要作用 ,检测卵巢组织 P16蛋白的表达 ,可对患者的治疗方案选择及预后判断提供有价值的信息
Objective: To investigate the correlation between the expression of P16 protein encoded by multiple tumor suppressor genes and the biological characteristics of ovarian cancer and the prognosis of patients. Methods: Immunohistochemical S-P method was used to detect the expression of P16 protein in 58 cases of human ovarian cancer. Results: (1) The positive expression rates of P16 protein in different histopathological types of ovarian cancer were different, which showed that the positive rate of P16 protein expression in poorly differentiated adenocarcinoma was lower than that in borderline tumor (P <0.05) ). (2) The positive rate of P16 protein in ovarian cancer was significantly lower than that in those without metastasis (P <0.01) in patients with lymph node and omental metastasis, but the positive rate There was no significant difference between primary tumor and metastasis (P> 0.05). (3) The positive rate of P16 protein expression in ovarian cancer tissues was lower than that of patients with postoperative survival of more than 2 years, the difference was significant (P <0.05) in patients with postoperative survival less than or equal to 2 years. Conclusion: P16 protein plays an important role in inhibiting the occurrence and development of ovarian cancer. Detecting the expression of P16 protein in ovary tissue may provide valuable information for the treatment options and prognosis of patients